ClinicalTrials.gg
RecruitingNCT05325034GOAL-ASIAUpdated Oct 8, 2026

Guideline Oriented Approach To Lipid Lowering In Asia-Pacific

An interventional study of Early Intervention in Cardiovascular Diseases, Acute Coronary Syndrome and Atherosclerosis, sponsored by Stephen Nicholls. Recruiting at 22 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Stephen Nicholls · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study.

Patients will be recruited during hospitalisation and be randomised to a multifaceted intervention to be delivered either 'early' (baseline) or 'late' (6 months), in a 1:1 fashion.

Read the detailed description

The study will be conducted over two phases.

In phase I (0-6 months), participants randomized to 'early' will receive the intervention at baseline through 6 months, while those randomized to 'late' will receive standard-of-care and represent a control arm over this period.

In phase II (6 to 12 months), those randomized to 'late' will receive the intervention at 6 months, while the 'early' group will continue in follow-up.

Multifaceted Intervention The intervention aims to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s). The intervention is deliberately nested within routine clinical care to enhance the generalisability of the findings beyond a research environment and to reflect other elements of real world practice.

  • Patient-and-clinician 'Cholesterol score card'. This passport-sized document will serve as a communication, engagement and activation tool for patients. It will be provided to participants at the commencement of the intervention and filled out at each study follow up visit. Participants will be encouraged to fill out sections at clinically-driven follow up appointments with their treating clinicians (e.g. general practitioner, cardiologist). The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies.
  • Risk stratification for recurrent events. As part of the intervention, each participant will have their SMART Risk score of a recurrent event assessed using the 'U-prevent' online calculator. In addition, each participant's Lp(a) will be measured and presented graphically on a continuum of risk. Both of these risk assessments will be sent to the treating primary care clinician and a copy provided to the participant.

Standard of care Participants allocated to 'late' will receive standard-of-care for the first 6 months which involves the provision of the participant's lipid profile to their nominated primary care physician/general practitioner at 6 weeks, 3 months and 6 months.

02

Conditions studied

  • Cardiovascular Diseases
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Hypercholesterolemia

Keywords

  • Acute Coronary Syndrome
  • Lipid management
  • Cholesterol
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

This is the only study on the registry with Stephen Nicholls as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age
  • Admission for Type I myocardial infarction

Exclusion criteria

Exclusion Criteria:

  • LDL \<1.4mmol/L at baseline
  • Unable to provide contact details of primary care physician/general practitioner
  • Unable to provide written .
  • Unlikely to survive >12 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Early intervention

    Participants randomised to 'early' will receive the intervention at baseline through 6 months. while those randomised to 'late' will receive standard-of-care and represent a control arm over this period.

    Behavioral: Early Intervention

  • Other
    Late intervention

    Those randomised to 'late' will receive standard-of-care and represent a control arm to the early intervention group.

    Behavioral: Early Intervention

Interventions

  • BehavioralEarly Intervention

    Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s). The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies.

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving an LDL <1.4mmol/L

    Proportion of patients achieving an LDL \<1.4mmol/L at 6 months. This will be determined from values obtained through local laboratory testing.

    Time frame: 6 months

Secondary outcomes

  1. Proportion of patients who undergo intensification of lipid-lowering therapy

    Proportion of patients who undergo intensification of lipid-lowering therapy in 6 months

    Time frame: 6 months

  2. Proportion of patients prescribed high-intensity statin

    Proportion of patients prescribed a guideline-recommended high-intensity statin through 6 months

    Time frame: 6 months

  3. Proportion of patients prescribed high-intensity statin at 6 months

    Proportion of patients prescribed a guideline-recommended high-intensity statin at 6 months

    Time frame: 6 months

  4. Adherence to lipid lowering therapy

    Proportion of patients reporting high levels of adherence to their lipid lowering therapy at 6 months

    Time frame: 6 months

  5. Patient activation and engagement in care

    Level of patient activation and engagement in their care at 6 months compared with baseline

    Time frame: 6 months

  6. Proportion of patients achieving LDL<1.4mmol/L at 12 months

    Proportion of patients achieving LDL\<1.4mmol/L at 12 months

    Time frame: 12 months

07

Study locations

11 of 22 sites recruiting
  • Illawarra Shoalhaven Local Health District
    Wollongong, New South Wales 2500, Australia
    Recruiting
    • Stephen Mackay · Contact
    • Astin Lee · Principal investigator
  • Cairns & Hinterland Hospital & Health Service
    Cairns, Queensland 4870, Australia
    Recruiting
    • Sue Dixon · Contact
    • Gregory Starmer · Principal investigator
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
    Not yet recruiting
    • Fiona Wollaston · Contact
    • Philip Aylward · Principal investigator
  • Monash Health
    Clayton, Victoria 3800, Australia
    Recruiting
    • Domenic Sacca · Contactdomenic.sacca@monash.edu · +61423245187
    • Stephen Nicholls, MBBS · Principal investigator
    • Adam Nelson, MBBS · Principal investigator
  • Western Health
    Melbourne, Victoria 3011, Australia
    Recruiting
  • Affiliated Zhongshan Hospital of Dalian University
    Dalian, Liaoning 116001, China
    Recruiting
    • Minglian Gong · Contactgongml777@126.com · +86 411 8561 4849
    • Minglian Gong · Principal investigator
  • All India Institute of Medical Sciences
    New Delhi, 360110, India
    Recruiting
  • Fukuoka University Hospital
    Fukuoka, Japan
    Not yet recruiting
    • Kohei Takata · Contact
    • Kohei Takata · Principal investigator
  • Kyorin University Hospital
    Mitaka, Japan
    Not yet recruiting
    • Sayaka Funabashi · Contact
    • Sayaka Funabashi · Principal investigator
  • National Cerebral and Cardiovascular Center
    Osaka, Japan
    Recruiting
    • Yu Kataoka · Contact
    • Yu Kataoka · Principal investigator
    • Satoshi Honda · Sub investigator
  • Osaka Medical and Pharmaceutical University Hospital
    Osaka, Japan
    Not yet recruiting
    • Daisuke Shishikura · Contact
    • Daisuke Shishikura · Principal investigator
  • University Teknologi MARA, Hospital UiTM, UiTM Medical Centre
    Shah Alam, Selangor, Malaysia
    Not yet recruiting
    • Sazzli Kasim · Contact
    • Sazzli Kasim · Principal investigator
  • National Heart Institute
    Kuala Lumpur, 50400, Malaysia
    Recruiting
    • Fatini Husain · Contactnfatini@ijn.com.my · +60 3-2617 8200
    • Rafidah Abu Bakar · Principal investigator
  • University of Malaysia Medical Centre
    Kuala Lumpur, 59100, Malaysia
    Recruiting
  • National Heart Centre
    Singapore, Singapore
    Recruiting
    • Khung Keong Yeo · Contact
    • Khung Keong Yeo · Principal investigator
  • National University Hospital Singapore (NUHS)
    Singapore, Singapore
    Not yet recruiting
    • Sock-Hwee Tan · Contact
    • Mark Chan · Principal investigator
  • PyeongChon Hallym University Sacred Heart Hospital
    Pyeongchon, Gyeonggi Province, South Korea
    Not yet recruiting
    • Sang-Ho Jo · Contact
    • Sang-Ho Jo, MD · Principal investigator
  • Kangnam Hallym University Sacred Heart Hospital
    Seoul, South Korea
    Not yet recruiting
    • Jung-Rae Cho · Contact
    • Jung-Rae Cho, MD · Principal investigator
  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
    Recruiting
    • Wen-hui Tseng · Contactiamywen@gmail.com · +886 6 275 7575
    • Yi-Heng Li · Principal investigator
  • Siriraj Hospital
    Bangkok, Thailand
    Not yet recruiting
    • Rungroj Krittayaphong · Contact
    • Rungroj Krittayaphong · Principal investigator
  • Srinagarind Hospital and Queen Sirikit Heart Center of the Northeast
    Khon Kaen, Thailand
    Not yet recruiting
    • Burabha Pussadhamma · Contact
    • Burabha Pussadhamma · Principal investigator
  • Songklanagarind Hospital
    Songkhla, Thailand
    Not yet recruiting
    • Ply Chichareon · Contact
    • Ply Chichareon · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 51 months is above that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2022
First posted
Apr 13, 2022
StartActual
Sep 15, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, oversight details and site details
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 3 other changes: verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05325034
Lead sponsor
Stephen Nicholls
Collaborators
Amgen
Responsible party
Stephen Nicholls (Professor, Monash University) — Sponsor-investigator
First posted
Apr 13, 2022
Start date
Sep 15, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Julie Butters, BHSc, MBA
Contact
julie.butters@monash.edu
61 434679018
Stephen Nicholls, MBBS, PhD
principal investigator · Monash University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion